JP2019535785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535785A5 JP2019535785A5 JP2019528489A JP2019528489A JP2019535785A5 JP 2019535785 A5 JP2019535785 A5 JP 2019535785A5 JP 2019528489 A JP2019528489 A JP 2019528489A JP 2019528489 A JP2019528489 A JP 2019528489A JP 2019535785 A5 JP2019535785 A5 JP 2019535785A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- insulin
- subject
- mace
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 102000004877 Insulin Human genes 0.000 claims 9
- 108090001061 Insulin Proteins 0.000 claims 9
- 229940125396 insulin Drugs 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 206010027525 Microalbuminuria Diseases 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 229960004225 insulin degludec Drugs 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 201000001474 proteinuria Diseases 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 108010057186 Insulin Glargine Proteins 0.000 claims 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 230000008321 arterial blood flow Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 229960001089 dobutamine Drugs 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 108010050259 insulin degludec Proteins 0.000 claims 1
- 229960002869 insulin glargine Drugs 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 238000012633 nuclear imaging Methods 0.000 claims 1
- 239000003538 oral antidiabetic agent Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200906 | 2016-11-28 | ||
| EP16200906.2 | 2016-11-28 | ||
| EP17174682.9 | 2017-06-07 | ||
| EP17174682 | 2017-06-07 | ||
| PCT/EP2017/080600 WO2018096162A1 (en) | 2016-11-28 | 2017-11-28 | Insulin degludec in cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535785A JP2019535785A (ja) | 2019-12-12 |
| JP2019535785A5 true JP2019535785A5 (enExample) | 2020-12-17 |
| JP7193455B2 JP7193455B2 (ja) | 2022-12-20 |
Family
ID=60937677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528489A Active JP7193455B2 (ja) | 2016-11-28 | 2017-11-28 | 心血管状態におけるインスリンデグルデク |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11278596B2 (enExample) |
| EP (1) | EP3544683A1 (enExample) |
| JP (1) | JP7193455B2 (enExample) |
| CN (1) | CN110022935A (enExample) |
| MA (1) | MA46897A (enExample) |
| WO (1) | WO2018096162A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3544683A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| AR112015A1 (es) | 2017-06-09 | 2019-09-11 | Novo Nordisk As | Composiciones sólidas para administración oral |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
| CN113773397B (zh) * | 2020-06-10 | 2023-10-20 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| AU2004261353B2 (en) | 2003-08-05 | 2009-12-10 | Novo Nordisk A/S | Novel insulin derivatives |
| IN2014KN02335A (enExample) * | 2012-03-28 | 2015-05-01 | Sanofi Sa | |
| US20160296602A1 (en) | 2013-03-20 | 2016-10-13 | Novo Nordisk A/S | Dosing Regimen |
| EP2991672A1 (en) * | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| MA46890A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| EP3544683A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
-
2017
- 2017-11-28 EP EP17825753.1A patent/EP3544683A1/en not_active Withdrawn
- 2017-11-28 US US16/463,598 patent/US11278596B2/en active Active
- 2017-11-28 JP JP2019528489A patent/JP7193455B2/ja active Active
- 2017-11-28 MA MA046897A patent/MA46897A/fr unknown
- 2017-11-28 CN CN201780073496.7A patent/CN110022935A/zh active Pending
- 2017-11-28 WO PCT/EP2017/080600 patent/WO2018096162A1/en not_active Ceased
-
2022
- 2022-02-08 US US17/667,223 patent/US12233114B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deacon | A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials | |
| Filippatos et al. | SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses | |
| Strain et al. | Diabetes, cardiovascular disease and the microcirculation | |
| FI3750535T3 (fi) | Menetelmiä sydän- ja verisuonitautitapahtumien riskin vähentämiseksi tutkittavalla | |
| Sloth-Nielsen et al. | Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis | |
| RU2768283C2 (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| Janez et al. | Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group | |
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| JP2016539164A5 (enExample) | ||
| JP7193455B2 (ja) | 心血管状態におけるインスリンデグルデク | |
| Feng et al. | Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes | |
| JP2019535791A5 (enExample) | ||
| Heusch et al. | Recruitment of inotropic reserve in “stunned” myocardium by the cardiotonic agent AR-L 57 | |
| Li et al. | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure | |
| CA3013532C (en) | Liraglutide in cardiovascular conditions | |
| Sedrak et al. | Evolving role of double and triple therapy with GLP-1 receptor agonists in obesity and cardiovascular disease | |
| Katsiki et al. | Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes | |
| KEITH et al. | RECESSION OF NEURORETINOPATHY DURING THE COURSE OF MALIGNANT HYPERTENSION: Its Occurrence in Fifteen Patients Who Did Not Receive Directed Therapy | |
| Breite et al. | Changing Fields-Diabetes Medications Invading the Cardiovascular Space | |
| Khutsoane | Liraglutide, an incretin mimetic: drug trends | |
| Maji et al. | A review on the role of peroxisome prolifertor-activated receptor-γ agonists and hybrids in type 2 diabetes and cardiomyopathy | |
| Fronczyk et al. | Clinical and ECG patterns of pseudoinfarction in a young man with type 1 diabetes, diabetic ketoacidosis and normokalaemia | |
| Varadhan et al. | Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent | |
| Filippas-Ntekouan | Effect of SGLT-2 inhibitors on the serum and urine metabolome in patients with type 2 diabetes mellitus | |
| Rafi et al. | Comparison of Empagliflozin-Linagliptin with Empagliflozin-Metformin Combination Therapy in Assessing Cardiovascular Profile and Anemia in Type 2 Diabetic Patients |